Key facts
- This page summarizes Abigail L. Jenkins's Form 4 filing for Gamida Cell Ltd..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Oct 2023, 16:40.
Abigail L. Jenkins - 19 Oct 2023 Form 4 Insider Report for Gamida Cell Ltd.
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- N/A
- Reported as of
- 19 Oct 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Oct 2023, 16:40:48 UTC
- Prior SEC filing
- 04 Oct 2022
- Next SEC filing
- 26 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joshua F. Patterson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Abigail L. Jenkins filed Form 4 for Gamida Cell Ltd. on 20 Oct 2023.
Change
- Previous filing in this sequence was filed on 04 Oct 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GMDA
transaction
Ordinary Shares
Award
- Transaction value
- $0
- Shares
- +109,013
- Change %
- +41%
- Price
- $0.000000
- Shares after
- 375,142
- Date
- 19 Oct 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GMDA
transaction
Derivative
Employee Share Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +217,954
- Change %
- Price
- $0.000000
- Shares after
- 217,954
- Date
- 19 Oct 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 217,954
- Exercise price
- $1.59
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The restricted stock unit ("RSU") award was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the award at the annual general meeting of the shareholders on October 19, 2023.
Footnote F2
Represents an RSU award, which vested or shall vest with respect to 33% of the RSUs, on each of August 8, 2023 and August 8, 2024, respectively, and with respect to 34% of the RSUs, on August 8, 2025. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date.
Footnote F3
The option grant was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on October 19, 2023.
Footnote F4
33% of the shares subject to the option award vested or shall vest on each of August 8, 2023 and August 8, 2024, respectively, and 34% of the shares subject to the option award shall vest on August 8, 2025, subject to the Reporting Person's continuous service through such vesting date.